دورية أكاديمية
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m IDH1 ) acute myeloid leukemia (AML).
| العنوان: | Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m IDH1 ) acute myeloid leukemia (AML). |
|---|---|
| المؤلفون: | Cortes J; Department of Medicine, Georgia Cancer Center, Augusta University, Augusta, GA, USA., Jonas BA; Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA, USA., Schiller G; Department of Internal Medicine, Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA., Mims A; Division of Hematology, The Ohio State University, Columbus, OH, USA., Roboz GJ; Department of Hematology and Medical Oncology, Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY, USA., Wei AH; Department of Haematology, The Alfred Hospital, Melbourne, Australia., Montesinos P; Department of Hematology, Hospital Universitari i Politècnic La Fe, Valencia, Spain., Ferrell PB; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Yee KW; Cancer Clinical Research Unit, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Fenaux P; Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France., Schwarer A; Department of Hematology, Box Hill Hospital, Monash University and Eastern Health Clinical School, Melbourne, Australia., Watts JM; Division of Hematology, Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA. |
| المصدر: | Leukemia & lymphoma [Leuk Lymphoma] 2024 Aug; Vol. 65 (8), pp. 1145-1152. Date of Electronic Publication: 2024 Mar 27. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: [Philadelphia, PA] : Taylor & Francis Original Publication: Chur ; New York : London, UK : Harwood Academic Publishers ; Distributed by STBS, 1989- |
| مواضيع طبية MeSH: | Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics , Isocitrate Dehydrogenase*/genetics , Isocitrate Dehydrogenase*/antagonists & inhibitors , Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use , Bridged Bicyclo Compounds, Heterocyclic*/adverse effects , Sulfonamides*/therapeutic use , Sulfonamides*/adverse effects , Mutation*, Humans ; Middle Aged ; Female ; Male ; Aged ; Adult ; Pyridines/therapeutic use ; Pyridines/adverse effects ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Remission Induction ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/adverse effects ; Drug Resistance, Neoplasm/genetics ; Aged, 80 and over |
| مستخلص: | Olutasidenib, a potent, selective, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, is FDA-approved for relapsed/refractory (R/R) acute myeloid leukemia (AML). Here we report efficacy and safety of olutasidenib in 18 patients with m IDH1 AML who were relapsed (10), refractory (6) or had complete remission with incomplete hematologic recovery (CRi; 2) to a venetoclax combination. Of the 16 patients who were R/R, 4 (25%) achieved complete remission (CR), one (6.3%) achieved CR with partial hematologic recovery (CRh), and 7 (43.8%) achieved a composite complete remission (CRc). Median time to CRc was 1.9 months (range 1-2.8). As of data cutoff (18 June 2021), median duration of CRc was not reached (range, 1.2-NR, ongoing at 30.4+ months). Both patients with CRi at study entry achieved a CR. Safety was consistent with the overall profile of olutasidenib. Olutasidenib offers a valuable treatment option for patients with m IDH1 AML previously treated with venetoclax. |
| فهرسة مساهمة: | Keywords: IDH1 mutation; Olutasidenib; acute myeloid leukemia |
| المشرفين على المادة: | EC 1.1.1.41 (Isocitrate Dehydrogenase) 0 (Bridged Bicyclo Compounds, Heterocyclic) 0 (Sulfonamides) N54AIC43PW (venetoclax) 0 (Pyridines) EC 1.1.1.42. (IDH1 protein, human) 0 (Antineoplastic Agents) |
| تواريخ الأحداث: | Date Created: 20240328 Date Completed: 20240723 Latest Revision: 20240822 |
| رمز التحديث: | 20240822 |
| DOI: | 10.1080/10428194.2024.2333451 |
| PMID: | 38538632 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1029-2403 |
|---|---|
| DOI: | 10.1080/10428194.2024.2333451 |